Moreover, fusion genes have also been reported in invasive mucinous adenocarcinoma29 and squamous and small‐cell lung cancers,30 and their exploration may soon be required in therapeutic management.31 Molecular pathology laboratories have already started receiving requests for exploration of various new fusions, for example, NTRK in lung cancer, FGFR2 in colorectal cancer, BRAF in pilocytic astrocytoma. The gene discussed is FGFR2; the disease is lung carcinoma.